Publicaciones en las que colabora con MARÍA PILAR ESCRIBANO SUBÍAS (32)

2023

  1. A mutation responsible for impaired detection by the Xpert SARS-CoV-2 assay independently emerged in different lineages during the SARS-CoV-2 pandemic

    BMC Microbiology, Vol. 23, Núm. 1

2022

  1. Different performance of three point-of-care SARS-CoV-2 antigen detection devices in symptomatic patients and close asymptomatic contacts: a real-life study

    Clinical Microbiology and Infection, Vol. 28, Núm. 6, pp. 865-870

  2. High incidence of COVID-19 at nursing homes in Madrid, Spain, despite preventive measures

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 3, pp. 288-292

  3. Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission

    Journal of Fungi, Vol. 8, Núm. 3

  4. Nosocomial Transmission of SARS-CoV-2 Involving Vaccinated Health Care Workers

    Microbiology Spectrum, Vol. 10, Núm. 1

2021

  1. Inference of active viral replication in cases with sustained positive reverse transcription-PCR results for SARS-CoV-2

    Journal of Clinical Microbiology, Vol. 59, Núm. 2

  2. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

    Mycoses, Vol. 64, Núm. 2, pp. 132-143

  3. Lack of relationship between genotype and virulence in Candida species

    Revista Iberoamericana de Micologia, Vol. 38, Núm. 1, pp. 9-11

  4. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection

    Clinical Microbiology and Infection, Vol. 27, Núm. 5, pp. 758-761

2020

  1. Candidemia Candida albicans clusters have higher tendency to form biofilms than singleton genotypes†

    Medical mycology, Vol. 58, Núm. 7, pp. 887-895

  2. Corrigendum to ‘Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect’ [Clinical Microbiology and Infection, Volume 24, (Issue 12) (December 2018) Pages 1343.e1-1343.e4](S1198743X18305214)(10.1016/j.cmi.2018.07.006)

    Clinical Microbiology and Infection

  3. Corrigendum to “Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect” [Clin Microbiol Infect 24 (12) (December 2018) 1343.e1-1343.e4](10.1016/j.cmi.2018.07.006)

    Clinical Microbiology and Infection

  4. Erratum: Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates (PLOS ONE (2017) 12:6 (e0179136) DOI: 10.1371/Journal.pone.0179136)

    PLoS ONE

  5. Erratum: Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect (Clinical Microbiology and Infection (2018) 24(12) (1343.e1–1343.e4), (S1198743X18305214), (10.1016/j.cmi.2018.07.006))

    Clinical Microbiology and Infection

  6. Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Candida Causing Candidemia at Distant Geographical Areas

    Frontiers in Cellular and Infection Microbiology, Vol. 10

  7. Invasive Scedosporium and Lomentosora infections in the era of antifungal prophylaxis: A 20-year experience from a single centre in Spain

    Mycoses, Vol. 63, Núm. 11, pp. 1195-1202

  8. Outbreak of COVID-19 in a nursing home in Madrid

    Journal of Infection

  9. Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?

    Infectious Diseases and Therapy, Vol. 9, Núm. 1, pp. 137-149

2019

  1. Detection of Echinocandin-Resistant Candida glabrata in Blood Cultures Spiked with Different Percentages of FKS2 Mutants

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 3

  2. Erratum: Growth kinetics in Candida spp.: Differences between species and potential impact on antifungal susceptibility testing as described by the EUCAST (Medical Mycology (2018) DOI: 10.1093/mmy/myy097)

    Medical Mycology